Home・Lista de Ações・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Fechado

SetorSaúde

55.61 -1.01

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.3

Máximo

57.03

Indicadores-chave
By Trading Economics
Rendimento	-91M -214M
Vendas	8.7M 10M
EPS	-0.94
Margem de lucro	-2,102.79
Funcionários	393
EBITDA	7.3M -110M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+31.81% upside

Dividendos
By Acuity
Próximos Ganhos	9 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	907M 5.5B
Abertura anterior	56.62
Fecho anterior	55.61

Sentimento de Notícias

By Acuity

50%

149 / 339 Ranking em Healthcare

CRISPR Therapeutics AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de set. de 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

2 de set. de 2026, 19:46 UTC

CRISPR Therapeutics AG shares are lower today, continuing a four-day decline amid rising U.S. Treasury yields and inflationary pressures affecting the biotechnology sector.

1 de set. de 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, with no specific news identified to explain the movement. The stock has declined in three consecutive sessions.

31 de ago. de 2026, 23:06 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting stable performance amid broader economic sentiment and expectations for a potential rate hike.

29 de ago. de 2026, 00:02 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of notable weakness amid rising market expectations for an interest rate hike.

28 de ago. de 2026, 22:51 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, continuing a trend of weakness since Friday's close with no specific news identified.

27 de ago. de 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting overall strength despite a slight pullback from earlier highs. No specific news was identified.

26 de ago. de 2026, 23:02 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, maintaining strength above the 20-day moving average and near the upper end of their one-month range.

25 de ago. de 2026, 23:06 UTC

CRISPR Therapeutics AG shares are lower in after-market hours, reflecting a decline after Tuesday's close, despite a significant gain over the past month.

24 de ago. de 2026, 23:01 UTC

Shares of CRISPR Therapeutics AG declined in after-market trading, despite briefly recovering earlier in the session. The stock remains above its 20-day moving average.

21 de ago. de 2026, 23:36 UTC

CRISPR Therapeutics AG shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the one-month range's upper end.

20 de ago. de 2026, 19:51 UTC

Correlated Moves

Shares lower today amid broader market pressures; SPDR S&P Biotech declines.

19 de ago. de 2026, 23:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, continuing a decline since Wednesday's close amid notable volatility.

18 de ago. de 2026, 22:16 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting unusual downward momentum amid broader market declines in major U.S. tech stocks.

17 de ago. de 2026, 23:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market sentiment affecting small-cap stocks amid a slight decline in the Russell 2000 Index.

14 de ago. de 2026, 19:16 UTC

CRISPR Therapeutics AG shares are lower today amid broader investor caution following a decline in U.S. retail sales for July.

13 de ago. de 2026, 23:46 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid favorable economic conditions.

11 de ago. de 2026, 19:21 UTC

CRISPR Therapeutics AG shares are trading higher amid rising oil prices and inflation concerns ahead of upcoming U.S. inflation data. No specific news was identified.

10 de ago. de 2026, 23:06 UTC

No specific news was identified for CRISPR Therapeutics AG, which traded roughly flat during after-market hours, remaining near the upper end of its one-month range.

7 de ago. de 2026, 20:06 UTC

News

Correlated Moves

Social Media

CRISPR Therapeutics AG is gaining amid positive social media sentiment and bullish chart patterns, aligning with the upward trend in the ARK Genomic Revolution ETF.

6 de ago. de 2026, 22:06 UTC

Correlated Moves

CRISPR Therapeutics AG shares are higher in after-market hours, aligning with positive trends in the biotechnology sector and maintaining a position above its 20-day moving average.

5 de ago. de 2026, 23:16 UTC

CRISPR Therapeutics AG shares traded lower in after-market hours, settling above the 20-day moving average and within the middle of its one-month range.

4 de ago. de 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

3 de ago. de 2026, 23:02 UTC

Social Media

News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31 de jul. de 2026, 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30 de jul. de 2026, 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29 de jul. de 2026, 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28 de jul. de 2026, 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27 de jul. de 2026, 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23 de jul. de 2026, 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

Comparação entre Pares

Variação de preço

CRISPR Therapeutics AG Previsão

Preço-alvo

By TipRanks

31.81% parte superior

Previsão para 12 meses

Média 74.46 USD 31.81%

Máximo 110 USD

Mínimo 45 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para CRISPR Therapeutics AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para CRISPR Therapeutics AG - Dist nos últimos 3 meses.

Sentimento

By Acuity

149 / 339 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.